{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:27:10Z","timestamp":1784140030876,"version":"3.55.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jaad.2025.02.095","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T05:27:09Z","timestamp":1743226029000},"page":"499-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Differences of clinical and laboratory features between dipeptidyl peptidase-4 inhibitor-related and nondipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"93","author":[{"given":"Yi-Hsuan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2025.02.095_bib1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.02.095_bib2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/1346-8138.14245","article-title":"Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid","volume":"45","author":"Chijiwa","year":"2018","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.095_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13790","article-title":"Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: estimating the clinical profile and exploring intraclass differences","volume":"33","author":"Kridin","year":"2020","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2025.02.095_bib4","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/bjd.16479","article-title":"Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors","volume":"178","author":"Horikawa","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.02.095_bib5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/bjd.17690","article-title":"Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"180","author":"Garc\u00eda-D\u00edez","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225005390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225005390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T20:38:46Z","timestamp":1758659926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225005390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0190962225005390"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.02.095","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences of clinical and laboratory features between dipeptidyl peptidase-4 inhibitor-related and nondipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.02.095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}